Evidence map›Paper›PMID 34148056›Full record

ArticleOncogene2021

HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.

Yong Wu, Qinhao Guo, Xingzhu Ju, Zhixiang Hu, Lingfang Xia, Yu Deng, Ping Zhao, Meng Zhang, Yang Shao, Shenglin Huang and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yong Wu *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qinhao Guo *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xingzhu Ju *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhixiang Hu *Fudan University Shanghai Cancer Center, Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Lingfang XiaDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yu DengDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China.
Ping ZhaoDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200001, China.
Meng ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yang ShaoCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shenglin HuangFudan University Shanghai Cancer Center, Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0003-1279-0794
Xianghuo HeFudan University Shanghai Cancer Center, Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0001-8872-668X
Hao WenDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wenhao_fdc@163.com.ORCID http://orcid.org/0000-0002-9587-8742
Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wu.xh@fudan.edu.cn.ORCID http://orcid.org/0000-0002-7664-8327
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNFirst Affiliated Hospital Zhejiang University · CNRuijin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies suggest an important role for copy number alterations (CNAs) in cancer progression. However, CNAs of long intergenic noncoding RNAs (lincRNAs) in ovarian cancer (OC) and their potential functions have not been fully investigated. Here, based on analysis of The Cancer Genome Atlas (TCGA) database, we identified in this study an oncogenic lincRNA termed LINC00662 that exhibited a significant correlation between its CNA and its increased expression. LINC00662 overexpression is highly associated with malignant features in OC patients and is a prognostic indicator. LINC00662 significantly promotes OC cell proliferation and metastasis in vitro and in vivo. Mechanistically, LINC00662 is stabilized by heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1). Moreover, LINC00662 exerts oncogenic effects by interacting with glucose-regulated protein 78 (GRP78) and preventing its ubiquitination in OC cells, leading to activation of the oncogenic p38 MAPK signaling pathway. Taken together, our results define an oncogenic role for LINC00662 in OC progression mediated via GRP78/p38 signaling, with potential implications regarding therapeutic targets for OC.

Indexed as

Cell ProliferationDisease ProgressionEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsOvarian NeoplasmsRNA, Long NoncodingAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiceMice, Nudep38 Mitogen-Activated Protein KinasesPrognosisEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mousep38 Mitogen-Activated Protein KinasesRNA, Long Noncoding

Identifiers

PMID34148056
PMCPMC8298204
OpenAlexW3173881458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.